LAG3 and ovarian carcinoma: Lymphocyte-activating gene 3 (LAG3) associates with SHP-1/2, and LAG3/PD-1 collaboration limits CD8+ T-cell signaling, which dampened antitumor immunity in a murine ovarian cancer model [129].